Agomab Therapeutics NV: Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
GHENT, Belgium, December 14, 2023 Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).
The quest for youth has existed for centuries, despite the inevitable effects of time on the body. Research shows that skin aging in particular strongly depends on the genetic capital and lifestyle of each individual, in addition to external factors such as pollution, UV rays. Is it possible to slow the aging process down? This is certainly one of the consumer concerns of this century: to age; yes, but to age well and stay healthy. Consumers are increasingly attuned to the values of the.
First in the series to occur on Tuesday, April 25, 2023 at 11:00 AM ET
NORWOOD, Mass., April 18, 2023 /PRNewswire/ Corbus Pharmaceuticals Holdings, Inc. , a precision oncology company, today. | April 18, 2023